Answers are grounded in this paper and cite their sources.
Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. This result directly confirms earlier findings. This benefit is not attributable to changes in symptoms, despite substantial evidence of efficacy for psychosis. Evaluation of xanomeline/trospium's potential for cognitive enhancement in a well-controlled trial of stable patients with cognitive impairment is warranted.
No takes yet. Share an insight, caveat, or question.
Horan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: